Tiny sensor tracks blood sugar in preterm babies to boost brain health

NCT ID NCT05436925

Completed Knowledge-focused Sponsor: University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study placed a continuous glucose monitor (CGM) on 24 preterm infants born before 31 weeks to track their blood sugar levels for up to 10 days. The goal was to see how well the device detects high and low blood sugar, and to link those readings to the babies' growth and brain development over time. The CGM was used for research only, not to guide treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dexcom G6 continuous glucose monitor (CGM)
What this could lead to: If successful, this could help doctors better manage blood sugar in preterm infants, potentially improving their growth and brain development.
What could go wrong: This is a small, early-stage study with only 24 infants, so results may not apply to all preterm babies. The CGM is used for research only, not for diagnosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERGLYCEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperglycemia hypoglycemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERGLYCEMIA VERY LOW BIRTH WEIGHT INFANT VERY PRETERM MATURITY OF INFANT

Contacts and locations

Locations

University of Minnesota

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.